Ad-hoc News

02.09.2015

MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent.

23.07.2015

The Supervisory Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) today appointed Dr. Mariola Söhngen, co-founder of PAION AG (and Management Board member up to October 31, 2015, as Chief Medical Officer; CMO), as Member of the Executive Board and...

17.06.2015

Today, the chairman of the supervisory board of MOLOGEN AG (ISIN DE0006637200/WKN 663720), Mr Oliver Krautscheid, informed the company that he will resign from his office as member and chairman of the supervisory board with effect as of the...

22.04.2015

MOLOGEN AG (ISIN DE0006637200/WKN 663720) successfully placed new shares from the cash capital increase resolved on 24 March 2015 with indirect subscription rights of the existing shareholders and subsequent international private placement with...

30.03.2015

Today, the executive board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) fixed, with the approval of the supervisory board, the subscription price for the capital increase against contributions in cash with indirect subscription rights for existing...

24.03.2015

Today, the executive board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) resolved, with the approval of the supervisory board, to increase the share capital of the company against contributions in cash and with indirect subscription rights for...

       

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.